Clinical trial
A Study of Aleglitazar in Patients With Type 2 Diabetes
NCT00388518 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00388518 |
|---|---|
| Title | A Study of Aleglitazar in Patients With Type 2 Diabetes |
| Official title | A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus Type 2 |
| Intervention type | Drug |
| Interventions | Actos, Placebo, aleglitazar |
| Enrollment | 332 |
| Start date | Nov 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Oct 17, 2006 |
| Last update posted | Nov 2, 2016 |
| Countries | Greece, Hong Kong, Italy, Mexico, Romania, Russia, Serbia, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: